ViralVacDB: A manually curated repository of viral vaccines.

Clicks: 173
ID: 277116
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #7 of 7 articles by views in Drug discovery today

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Over the years, numerous vaccines have been developed against viral infections; however, a complete database that provides comprehensive information on viral vaccines has been lacking. In this review, along with our freely accessible database ViralVacDB, we provide details of the viral vaccines, their type, routes of administration and approving agencies. This repository systematically covers additional information such as disease name, adjuvant, manufacturer, clinical status, age and dosage against 422 viral vaccines, including 145 approved vaccines and 277 in clinical trials. We anticipate that this database will be highly beneficial to researchers and others working in pharmaceuticals and immuno-informatics.
Reference Key
tripathi2023viralvacdbdrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tripathi, Sadhana;Sharma, Neelam;Naorem, Leimarembi Devi;Raghava, Gajendra P S;
Journal Drug discovery today
Year 2023
DOI
10.1016/j.drudis.2023.103523
URL
Keywords
clinical trials vaccines viral diseases database virus approved vaccines

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.